Compare Bristol-Myers Squibb Co (BMY) vs Iron Mountain Inc (IRM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Iron Mountain Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.7 (market cap $129.94B), while Iron Mountain Inc trades at $124.1 (market cap $36.44B). The key difference: Bristol-Myers Squibb Co is far larger — about 3.6× Iron Mountain Inc's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | IRM | |
|---|---|---|
Market Cap | $129.94B | $36.44B |
Sector | Health | Real Estate |
52-Week High | $65.89 | $133.06 |
52-Week Low | $42.60 | $78.86 |
Enterprise Value | $163.92B | $55.85B |
Dividend Yield | 3.96% | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
Iron Mountain (IRM) trades at $121.56, up 0.34% today, with strong earnings beats in recent quarters and a bullish analyst consensus price target of $141.50. The stock shows bearish technical signals but benefits from robust revenue growth, particularly in data centers and digital solutions, though high debt levels and declining profit margins pose challenges. Recent news highlights CEO stock sales and institutional buying activity.
Outlook: IRM offers growth potential from data center expansion and recurring revenue streams, supported by positive analyst ratings. Key risks include elevated debt, margin pressure, and competitive threats. Investors should weigh strong operational performance against financial leverage and market sentiment shifts for balanced decision-making.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →
